Prothena Biosciences today engaged FLG Partners as interim CFO and to effect the spinout of the company from Elan Pharmaceuticals (NYSE:ELN). FLG Partner: Bern Whitney.
Sign Up for Periodic Updates
Enter your email address below to receive updates from FLG Partners.
